Evaluating the Role of Bedrest on the Prevention of Hypertensive Diseases of Pregnancy and Growth Restriction
- 1 January 2008
- journal article
- clinical trial
- Published by Taylor & Francis Ltd in Hypertension in Pregnancy
- Vol. 27 (2), 197-205
- https://doi.org/10.1080/10641950701826273
Abstract
Evaluating the effect of restricted activity on the development of preeclampsia under experimental clinical settings has been compromised by inherent selection bias and differential misclassification. The aim of our study was to overcome such limitations by using hospitalized bedrest for preterm labor/birth-related indications as an unbiased measure of restricted activity and evaluate its effect on the development of hypertensive diseases of pregnancy. We conducted a retrospective cohort study using data from the McGill Obstetrical and Neonatal Database on all pregnancies that took place between 1991 and 2001. We defined "exposure" as hospitalized bed rest for preterm labor/birth related indications and used unconditional logistic regression models to estimate its adjusted effect on the development of hypertensive diseases of pregnancy. Data were available on 36,140 pregnancies. 677 women were hospitalized and prescribed bedrest for either preterm contractions (71%), preterm premature rupture of membranes (18%), an incompetent cervix (8%), or other indications. Among all women, bedrest was associated with a significant reduced risk for developing preeclampsia, 0.27 (0.16-0.48). In a stratified analysis, women delivering prior to 34 weeks of gestation had an even more pronounced reduced risk for developing preeclampsia 0.12 (0.03-0.50) as well as a reduced risk for developing intrauterine growth restriction 0.38 (0.18-0.84). When strictly adhered to, bedrest may be an effective measure in the prevention of preeclampsia and early intrauterine growth restriction.Keywords
This publication has 12 references indexed in Scilit:
- Mapping the Theories of Preeclampsia and the Role of Angiogenic FactorsObstetrics & Gynecology, 2007
- Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restrictionAmerican Journal of Obstetrics and Gynecology, 2006
- Fractional Excretion of Angiogenic Factors in Women With Severe PreeclampsiaObstetrics & Gynecology, 2006
- Soluble Vascular Endothelial Growth Factor Receptor-1 (sFLT-1) Mediates Downregulation of FLT-1 and Prevents Activated Neutrophils From Women With Preeclampsia From Additional Migration by VEGFCirculation Research, 2005
- An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2005
- Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnanciesAmerican Journal of Obstetrics and Gynecology, 2005
- Urinary Placental Growth Factor and Risk of PreeclampsiaJama-Journal Of The American Medical Association, 2005
- Circulating Angiogenic Factors and the Risk of PreeclampsiaNew England Journal of Medicine, 2004
- Nutritional factors and rest reduce pregnancy-induced hypertension and pre-eclampsia in positive roll-over test primigravidasInternational Journal of Gynecology & Obstetrics, 1993
- Effective prevention of gestational hypertension in nulliparous women at high risk as identified by the rollover testAmerican Journal of Obstetrics and Gynecology, 1983